Bristol-Myers Squibb Services Unlimited Company

Oncology

The sponsor’s oncology portfolio spans non-small cell lung cancer, melanoma, urothelial cancer, breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal cancers, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, bladder cancer, and myelofibrosis. It also includes studies in acute myeloid leukemia, myelodysplastic syndrome, primary central nervous system lymphoma, and other advanced solid tumors.

  • Immuno-oncology
  • Targeted therapy
  • Metastatic cancer
  • Hematologic malignancies
  • Perioperative and first-line cancer treatment

Research activity includes treatment of EGFR-mutated and KRAS G12C-mutant disease, as well as platinum-resistant and unresectable cancer settings.

Autoimmune and inflammatory disease

Clinical research in immune-mediated disease centers on systemic lupus erythematosus, cutaneous lupus erythematosus, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, idiopathic inflammatory myopathy, ulcerative colitis, and atopic dermatitis.

  • Systemic lupus erythematosus
  • Psoriatic arthritis
  • Psoriasis
  • Inflammatory bowel disease
  • Connective tissue disease

Additional work extends to juvenile psoriatic arthritis and pediatric immune-mediated conditions.

Neurology and psychiatry

The sponsor funds trials in Alzheimer’s disease, including early and mild to moderate stages, with associated agitation and psychosis. Its neuroscience portfolio also includes bipolar I disorder, mania, schizophrenia, and relapsing remitting multiple sclerosis.

  • Alzheimer’s disease
  • Bipolar I disorder
  • Schizophrenia
  • Multiple sclerosis
  • Neuropsychiatric symptoms

Research also addresses primary central nervous system lymphoma within the broader neuro-oncology landscape.

Pulmonary and cardiovascular disease

Respiratory and cardiometabolic studies include idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and heart failure with preserved ejection fraction. Cardiovascular research also covers symptomatic obstructive hypertrophic cardiomyopathy.

  • Interstitial lung disease
  • Pulmonary fibrosis
  • Heart failure
  • Hypertrophic cardiomyopathy

These programs reflect interest in chronic cardiopulmonary disorders with significant unmet treatment need.

Hematology, transplantation, and rare disease

Additional clinical work includes sickle cell disease, renal transplantation, and adolescent renal allograft care, alongside studies in myelofibrosis and other hematologic disorders. The portfolio also extends to urothelial carcinoma and solid malignancies with high-risk or refractory features.

  • Sickle cell disease
  • Renal transplantation
  • Myelofibrosis
  • Urothelial carcinoma

Research activity in these areas spans both chronic disease management and oncology-linked rare conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

    Recruiting

    2 1 1
    France Germany Italy Poland Romania Spain +1
  • Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

    Recruiting

    2 1 1 1
    Belgium Denmark France Greece Italy The Netherlands +2
  • Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

    Recruiting

    3 1 1 1
    Austria Belgium Denmark France Germany Ireland +6
  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia France Germany +9
  • Study on the Safety and Effects of BMS-986470 for Patients with Sickle Cell Disease

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    France Italy The Netherlands Spain